RecruitingNCT03794076
Study of cromoglicate added to usual care for schizophrenia
About this title
Read the official source — NCT03794076Medication studyAges 18–65United States
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- PittsburghSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: April 1, 2019
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 160
- Sponsor
- Vishwajit Nimgaonkar, MD PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03794076
- Official title
Show the full official title
Cromoglicte Adjunctive Therapy for Outpatients With Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Pittsburgh
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vishwajit Nimgaonkar, MD PhD.
Does this study involve medication?
Yes. The study involves medication, including Cromoglycate and Placebo.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
